Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | Pembrolizumab monotherapy and pembro-axitinib for RCC

Michael Atkins • 15 Feb 2019
GU Cancers 2019
Genitourinary Cancer Kidney Cancer Axitinib Pembrolizumab
KEYNOTE-426 KEYNOTE-427

Speaking from the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Michael Atkins, MD, of Georgetown University, Washington, DC, discusses the promising results from the Phase II KEYNOTE-427 study with pembrolizumab (NCT02853344), and the Phase III KEYNOTE-426 trial (NCT02853331) looking at the combination of pembrolizumab with axitinib for treating advanced renal cell carcinoma (RCC).

More from Michael Atkins

1:46
Clinical trials in kidney cancer to look out for
Michael Atkins • 17 Feb 2023
1:34
Potential new biomarkers for advanced ccRCC treatment response identified
Michael Atkins • 17 Feb 2023
6:16
Treatment-free survival results of nivolumab and salvage nivolumab + ipilimumab for accRCC
Michael Atkins • 17 Feb 2023
1:44
TIVO-3: tivozanib hydrochloride vs sorafenib for refractory advanced RCC
Michael Atkins • 18 Feb 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals